Thailand’s “vaccine development,” in line with the BCG model in the field of medicine and vaccines, focuses on development with sustainability in mind. Although Thailand has the ability to produce vaccines in upstream areas, such as vaccine discovery, proof of concept, etc., from a one-year procurement, it becomes an obstacle when entrepreneurs are unable to plan long-term production, which affects the stability of the country's vaccine management. The goal of vaccine development under the BCG model is to develop vaccines for sale and prepare the development of new vaccines for industrial production, along with being able to test in clinical trials. The following driving guidelines have been set:

• To build an animal facility network that meets OECD GLP standards and that can support adequate demand;
• To develop a facility that can be certified according to OECD GLP/GMP standards, to support worldwide sales;
• To consider multi-year block grant funding and the ability to finance the private sector;
• To establish a development fund to promote investment and research and development;
• To designate multi-year procurement measures to support domestic producers and a vaccine block chain for stockpile management;
• To prepare pool procurement in commercial agreements to expand the market and increase bargaining power. 

Source: National Science and Technology Development Agency (NSTDA)

Tel: +66 2 564 8000